Uncommon Cents Investing LLC Decreases Stock Position in Johnson & Johnson (NYSE:JNJ)

Uncommon Cents Investing LLC cut its stake in shares of Johnson & Johnson (NYSE:JNJ) by 0.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 27,972 shares of the company’s stock after selling 208 shares during the quarter. Johnson & Johnson accounts for about 1.2% of Uncommon Cents Investing LLC’s investment portfolio, making the stock its 22nd largest holding. Uncommon Cents Investing LLC’s holdings in Johnson & Johnson were worth $4,045,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also bought and sold shares of JNJ. IFS Advisors LLC grew its holdings in shares of Johnson & Johnson by 138.9% in the fourth quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares during the last quarter. Highline Wealth Partners LLC bought a new stake in Johnson & Johnson in the 3rd quarter worth $31,000. RPg Family Wealth Advisory LLC purchased a new position in shares of Johnson & Johnson in the third quarter valued at about $35,000. Mowery & Schoenfeld Wealth Management LLC raised its stake in shares of Johnson & Johnson by 58.7% during the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock valued at $40,000 after acquiring an additional 91 shares during the last quarter. Finally, Activest Wealth Management purchased a new stake in shares of Johnson & Johnson during the third quarter worth about $40,000. 69.55% of the stock is currently owned by institutional investors.

Insiders Place Their Bets

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, December 12th. The stock was bought at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the acquisition, the director now owns 1,000 shares of the company’s stock, valued at $147,220. This represents a ∞ increase in their ownership of the stock. The purchase was disclosed in a filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.16% of the company’s stock.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on JNJ shares. Guggenheim increased their price objective on Johnson & Johnson from $156.00 to $162.00 and gave the stock a “neutral” rating in a report on Wednesday, November 6th. Morgan Stanley lifted their price target on shares of Johnson & Johnson from $169.00 to $175.00 and gave the company an “equal weight” rating in a report on Wednesday, October 16th. Wolfe Research began coverage on shares of Johnson & Johnson in a report on Friday, November 15th. They issued an “outperform” rating and a $190.00 price objective for the company. Royal Bank of Canada lifted their target price on shares of Johnson & Johnson from $178.00 to $181.00 and gave the company an “outperform” rating in a research note on Wednesday, October 16th. Finally, StockNews.com downgraded shares of Johnson & Johnson from a “strong-buy” rating to a “buy” rating in a research note on Friday, January 17th. Eight analysts have rated the stock with a hold rating and seven have given a buy rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $173.27.

Johnson & Johnson Stock Up 0.7 %

Shares of Johnson & Johnson stock opened at $148.10 on Wednesday. The company has a 50-day simple moving average of $148.35 and a two-hundred day simple moving average of $156.11. The stock has a market capitalization of $356.57 billion, a PE ratio of 21.43, a price-to-earnings-growth ratio of 2.39 and a beta of 0.51. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a debt-to-equity ratio of 0.45, a quick ratio of 0.79 and a current ratio of 1.03.

Johnson & Johnson Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.35%. Johnson & Johnson’s dividend payout ratio is 71.78%.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.